Avidity Biosciences Inc Stock price
Is Avidity Biosciences Inc a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?
As a Free StocksGuide user, you can view scores for all 9,100 stocks worldwide.
Key metrics
Avidity Biosciences Inc Stock Analysis
Analyst Opinions
8 Analysts have issued a Avidity Biosciences Inc forecast:
Analyst Opinions
8 Analysts have issued a Avidity Biosciences Inc forecast:
Don't miss a Thing! We will send you all news about Avidity Biosciences Inc directly to your mailbox free of charge.
If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.
Avidity Biosciences Inc Stock News
Company Profile
Avidity Biosciences, Inc., a biopharmaceutical company, engages in the development of oligonucleotide-based therapies. It develops antibody oligonucleotide conjugates (AOC) designed to treat a range of serious diseases. The company's lead product candidate is AOC 1001 for treatment of myotonic dystrophy type 1; and four other muscle programs, which focus on the treatment of muscle atrophy, duchenne muscular dystrophy, facioscapulohumeral muscular dystrophy, and Pompe disease. It utilizes its proprietary AOC platform to design, engineer, and develop therapeutics that combine tissue selectivity of monoclonal antibodies and precision of oligonucleotide therapies to access previously undruggable tissue and cell types, and target underlying genetic drivers of diseases. The company also has development programs that focuses on immune and other cell types. Avidity Biosciences, Inc. was founded in 2012 and is based in La Jolla, California.


